BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huguet JM, Cortés X, Bosca-Watts MM, Aguas M, Maroto N, Martí L, Amorós C, Paredes JM. Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. World J Clin Cases 2021; 9(36): 11285-11299 [PMID: 35071559 DOI: 10.12998/wjcc.v9.i36.11285] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Huguet JM, García-lorenzo V, Martí L, Paredes JM, Ramírez JJ, Pastor M, Ruiz L, Sanahuja A, Timoneda P, Sanchís L, Pérez GA, Boscá-watts MM. Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study. Biomedicines 2022;10:2130. [DOI: 10.3390/biomedicines10092130] [Reference Citation Analysis]